Electronic Patient Reporting of Symptoms During Cancer Treatment (PRO-TECT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03249090|
Recruitment Status : Recruiting
First Posted : August 15, 2017
Last Update Posted : July 23, 2019
|Condition or disease||Intervention/treatment||Phase|
|Advanced Cancer Metastatic Cancer||Other: Patient Self-Reporting of Symptoms Other: Usual Care Delivery||Not Applicable|
This is a cluster RCT at up to 50 sites where randomization will occur in a 1:1 ratio at the site level (not at the individual patient level). Therefore, up to 25 sites will be randomized to the PRO-TECT intervention arm (patient-reporting of symptoms plus access to standardized symptom management guideline), and up to 25 sites will be randomized to the control arm (usual care delivery plus access to standardized symptom management guideline). Specifically:
PROCEDURES AT ALL SITES (CONTROL SITES AND INTERVENTION SITES):
- Site staff (CRA and Nurse Champion required) will attend the site initiation webinar with UNC staff, including training for the PRO-Core online data management system and orientation to the symptom management guidelines.
- At enrollment, all participants will be given a booklet with patient-level symptom advice and a link to the content online.
- All participants will receive compensation for participation, mailed to them as gift cards by UNC.
- CRAs will train all participants how to complete outcomes questionnaires for the trial using the PRO-Core online system. Participants will be given a choice to complete these in clinic or from home online, or if necessary via paper in clinic (with the CRA entering the data into PRO-Core). If the patient does not self-complete this information, the CRA will contact them to collect the information and then enter it into PRO-Core. The outcomes questionnaires will be completed at baseline; and at month 1 (+/- 2 weeks); and at months 3, 6, 9, and 12/off-study (+/- 4 weeks each), and will be available in English, Spanish, or Mandarin Chinese. At each time point, the CRA will contact the participant to remind them about the upcoming questionnaire and offer help.
- Chart abstraction will be conducted by CRAs at baseline and at off-study for each participant, with data entered into the PRO-Core system. Date of death information will additionally be abstracted at 18 and 24 months, and possibly later per the UNC study team.
- CRAs will be asked to complete a feedback survey (entered by the CRA into the PRO-Core online system) and may be asked to participate in a brief telephone debriefing and/or site visit.
- Accrual will be monitored in a weekly teleconference between the UNC team and site CRAs.
ADDITIONAL PROCEDURES AT INTERVENTION SITES ONLY:
- At baseline, CRAs will also train patients to self-report symptoms and physical functioning using the PRO-Core system weekly for up to a year, with a choice to do this online or via an automated telephone system (patient choice), and a choice of English, Spanish, or Mandarin Chinese.
- Whenever a concerning symptom is reported, an automated "email alert" notification will be sent to the site CRA. The CRA will forward the email alert to the responsible clinical nurse (or other covering clinician) and CC the site's Nurse Champion. Within 72 hours, the CRA will document what action(s), if any, were taken by the nurse in response to the alert (entered by the CRA into a form in the PRO-Core system).
- A symptom report will be printed/generated by the site CRA whenever the patient has a clinic visit, and will be given to the oncologist and nurse caring for the patient.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1200 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||"PRO-TECT" Patient Reported Outcomes to Enhance Cancer Treatment|
|Actual Study Start Date :||October 30, 2017|
|Estimated Primary Completion Date :||December 2019|
|Estimated Study Completion Date :||September 2021|
Experimental: Patient Self-Reporting of Symptoms
Patients report symptoms weekly via web or automated telephone system. Email alerts to nurses for severe/worsening symptoms; printouts for clinicians at visits. Evidence based symptom management pathways provided to patients and clinicians.
Other: Patient Self-Reporting of Symptoms
At baseline, CRAs will train patients to self-report symptoms and physical functioning weekly for up to a year, with a choice to do so online or via an automated telephone system. Whenever a concerning symptom is reported, an automated "email alert" notification will be sent to the site CRA. The CRA will forward the alert to the responsible clinical nurse (or other covering clinician) and CC the site's Nurse Champion. Within 72 hours, the CRA will document what action(s), if any, were taken by the nurse in response to the alert (entered by the CRA into a form in the PRO-Core system). A symptom report will be printed/generated by the site CRA whenever the patient has a clinic visit and will be given to the oncologist and nurse caring for the patient.
Active Comparator: Usual Care Delivery
Evidence-based symptom management pathways provided to patients and clinicians
Other: Usual Care Delivery
Patients receive routine cancer care delivery with no additional systematic monitoring of symptoms
- Physical Functioning [ Time Frame: 3 months ]Physical functioning will be measured via the QLQ-C30
- Overall Survival [ Time Frame: Up to 24 months ]Based on the number of events observed. Overall survival will be compared between arms using a stratified log-rank rest.
- Emergency room/hospital utilization [ Time Frame: 12 months ]Emergency room/hospitalization will be compared between arms using stratified Fine-Gray competing risk regression with death a competing risk
- Duration of cancer treatment [ Time Frame: 12 months ]Duration of cancer treatment will be compared between arms using stratified Fine-Gray competing risk regression with death as a competing risk
- Health-related quality of life and symptom burden time [ Time Frame: 3 months ]Measured by QLQ-C30
- Patient Satisfaction/Communication [ Time Frame: 3 months ]Measured with Patient Satisfaction Questionnaires
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03249090
|Contact: Sydney Hensonemail@example.com|
|Contact: Amanda Bradleyfirstname.lastname@example.org|
Show 45 Study Locations
|Study Chair:||Ethan Basch, MD||University of North Carolina, Chapel Hill|